

Daxor's Blood Volume Analyzer (BVA-100®) To Be Used As a Key Metric in NIH Study of "Long Haul" COVID-19 Patients

Oak Ridge, TN - MAY 25, 2022 -- [Daxor Corporation](#) (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today participation in the National Institutes of Health (NIH) Intramural Research Program-sponsored study titled "An Observational Study of Neurologic Function after COVID-19 Infection" utilizing Daxor's BVA-100 (Blood Volume Analyzer, "BVA") technology. The study is being conducted under the leadership of Avindra Nath, M.D. at the National Institute of Neurological Disorders and Stroke (NINDS) located in Bethesda, Maryland.

Dr. David S. Goldstein, M.D., Ph.D., Lead Associate Investigator, NINDS, commented, "One of the mysteries of post-acute sequelae SARS-CoV-2 is the basis for non-specific, enduring, debilitating symptoms such as 'brain fog' executive dysfunction, exercise intolerance, and orthostatic intolerance. There are several potential mechanisms, including low blood volume. The 131I-albumin technique is a well-established method for measuring blood volume."

"We are honored to collaborate with such an esteemed group of investigators at one of the most important medical research centers in the world to provide unique medical insights into what may be affecting thousands suffering from 'Long Haul' COVID-19. BVA is used daily at leading hospital centers to treat patients and for groundbreaking medical research because of its unique accuracy and clinical utility," said Michael Feldschuh, CEO and President of Daxor Corporation.

Daxor's BVA-100 system is routinely used for numerous medical indications, including critical care, neuro critical care, hypertension, and heart failure. Daxor is currently under contract with the Department of Defense to develop a portable next-generation blood volume analyzer capable of faster measurement and a unique, patent-pending fluorescence technology.

About Daxor Corporation

[Daxor Corporation](#) (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 60,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing multicenter trials in the areas of COVID-19 and heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor's vision is optimal blood volume for all. For more information, please visit our website at Daxor.com.

Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:

Bret Shapiro

Sr. Managing Partner, CORE IR

1-516-222-2560

brets@coreir.com

DAXOR ANNOUNCES KEY MILESTONES ACHIEVED FOR MULTICENTER BVA-100® STUDY IN HOSPITALIZED PATIENTS WITH COVID-19

Patient Enrollment Complete and Data Analysis Commences with Daxor's Blood Volume Analysis Technology

Oak Ridge, TN, -- January 5, 2022 -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announces patient enrollment is complete and data analysis is underway in preparation for publication of the multi-center observational prospective study utilizing Daxor's BVA-100 (Blood Volume Analyzer, "BVA") technology in hospitalized COVID-19 patients. NYU Langone Health, Wake Forest School of Medicine and OHSU have been enrolling subjects since the onset of the pandemic.

Dr. Jan Bakker, MD, PhD, NYU Langone Health, and principal investigator, initiated this multi-center prospective study utilizing the BVA-100 blood test to understand fluid imbalances in COVID-19 patients as a result of initial research and recent data published in the journal *Critical Care*. The study, titled "Blood volume and albumin transudation in critically-ill COVID-19 patients," showed that COVID-19 patients suffer from significant capillary damage and blood volume deficits that care teams became aware of only through the use of the Daxor BVA-100 blood test.

"BVA is the only test that provides a unique measure of capillary permeability via its albumin tracer, an important insight into SARS-CoV-2 pathophysiology," said Jan Bakker, MD, PhD, NYU Langone Health. "With patient enrollment complete and data analysis underway, we aim to show that the implications of COVID as an endothelial disease utilizing this measure along with precise measurement of total blood, red cell and plasma volume could help guide the care of COVID-19 patients, thus promoting better treatment of these patients."

Jonathan Feldschuh, Chief Scientific Officer of Daxor, stated, "Accurate volume assessment allows for individualized care, ensuring circulatory integrity and optimal tissue perfusion. Our BVA technology provides clinicians with precise volume measurement superior to commonly used indirect estimates. We believe the study results will further validate and broaden the need for blood volume analysis to optimize treatment and improve outcomes for patients."

About Blood Volume Analysis and the BVA-100®

Daxor is the global leader in blood volume measurement technology, utilized by major healthcare systems in the United States. Blood volume analysis is an important measure of health, surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved multiple measures of patient

outcomes. In a randomized control trial (RCT) published in 2011 in the journal *Shock*, patients at a Level-1 trauma center ICU suffering predominantly from ARDS/sepsis/septic shock/hemorrhagic shock who received BVA-guided care showed significant benefits including a 66% lower mortality rate ($P < 0.03$), reducing mortality from 24% to 8%. Analysis showed 44% of BVA test results led to a change in treatment strategy ($P = 0.004$) that care teams would not have performed absent the data from the BVA volume status measure.

About Daxor Corporation

Daxor Corporation (NYSE: DXR) is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology enhances hospital performance metrics in a broad range of surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved multiple measures of patient outcomes. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor's vision is optimal blood volume for all. For more information, please visit our website at Daxor.com.

Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:

Bret Shapiro

Sr. Managing Partner, CORE IR

516-222-2560brets@coreir.com

THIRD HOSPITAL JOINS MULTICENTER COVID-19 BVA-100® BLOOD TEST STUDY

NEW YORK -- November 19, 2020 -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that Wake Forest Baptist Health will participate in an ongoing trial to treat patients hospitalized with COVID-19 utilizing Daxor's BVA-100 (Blood Volume Analyzer, "BVA") technology. Wake Forest School of Medicine is based in Winston-Salem, North Carolina, and is set to enroll patients under the leadership of Ashish K. Khanna, MD.

“Having such a prestigious academic and research center such as Wake Forest join the ongoing multi-center trial alongside Oregon Health & Science University and NYU Langone Health highlights the importance of BVA technology in helping clinicians understand COVID-based volume derangements to improve care and outcomes,” said Michael Feldschuh, CEO and President of Daxor. “SARS-CoV-2 attacks the endothelium causing volume derangement and capillary distress. Daxor’s BVA test is the first and only diagnostic test cleared by FDA that offers insights into patients’ capillary leak rate via its albumin tracer in addition to 98% accurate measure of plasma and red cell volume. Elevated leak rate has been shown as a prognostic marker associated with higher mortality, knowledge of it and volume status can be used to triage patients, guide treatment, and measure response to interventions.”

“We hope this important trial will help inform volume status and provide crucial insights into COVID-19 pathophysiology,” said Dr. Khanna, Associate Professor in Anesthesiology, Section Head for Research, Section in Critical Care Medicine, Wake Forest School of Medicine.

Daxor is the global leader in blood volume measurement technology, utilized by major hospitals in the United States. In a randomized control trial (RCT) published in the journal *Shock*, the BVA-100® has shown to reduce ICU mortality by 66% (P=0.03) and reduce ventilator days in patients suffering predominantly from acute respiratory distress syndrome and septic shock. Additionally, the analysis showed 44% of BVA test results led to a change in treatment strategy (P=0.004) that care teams would not have performed absent the data from the BVA volume status measure.

About Daxor Corporation

Daxor Corporation (NYSE: DXR) is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific

norms. The BVA technology enhances hospital performance metrics in a broad range of surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved multiple measures of patient outcomes. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor's vision is optimal blood volume for all. For more information, please visit our website at Daxor.com.

Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:

Bret Shapiro

Sr. Managing Partner, CORE IR

516-222-2560

brets@coreir.com

OREGON HEALTH & SCIENCE UNIVERSITY JOINS MULTICENTER COVID-19 BVA-100® STUDY

COVID-19 Investigation Continues at OHSU to Study Hospitalized Patients Utilizing Daxor's Blood Volume Analysis Technology

NEW YORK -- October 29, 2020 -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that Oregon Health & Science University ("OHSU"), the state's only comprehensive public academic health center, joins NYU Langone Health as the second site to participate in a trial to treat patients hospitalized with COVID-19 utilizing Daxor's BVA-100 (Blood Volume Analyzer, "BVA") technology. OHSU is based in Portland, Oregon, and is set to begin enrolling patients under the leadership of Martin A. Schreiber, M.D.

"We are thrilled to have OHSU, one of the leading academic and research centers in the United States, join NYU Langone Health in this critical multicenter COVID-19 BVA trial," said Michael Feldschuh, CEO and President of Daxor. "The exact quantification of total blood, red cell and plasma volume and knowledge of capillary status are unique to Daxor's BVA technology and provides clinicians precise volume measurement that is superior to commonly used indirect estimates. We believe our test can have a significant impact on patient triage, outcomes and optimal use of resources."

The BVA is the first and only diagnostic test cleared by the FDA that directly measures capillary permeability via its albumin tracer, a capability that provides crucial insight into COVID-19 pathophysiology. A persistently elevated leak rate is a prognostic marker associated with higher mortality, which can be used to triage patients, guide treatment, and measure response to interventions. This study aims to show the implications of COVID as an endothelial disease utilizing this unique measure.

"In light of the fact that the SARS-CoV-2 virus attacks the endothelium causing increasing permeability, this technology could help determine volume status in these patients as well as quantifying the 3rd spacing rate," said Dr. Schreiber, Professor of Surgery, Division of Trauma, Critical Care and Acute Care Surgery, OHSU School of Medicine.

In a randomized control trial (RCT) published in 2011 in the journal *Shock*, the BVA-100® has shown to reduce ICU mortality by 66% and reduce ventilator days in patients suffering predominantly from acute respiratory distress syndrome and septic shock. Additionally, the analysis showed 44% of BVA test results led to a change in treatment strategy (P=0.004) that care teams would not have performed absent the data from the BVA volume status measure.

About Daxor Corporation

Daxor Corporation (NYSE: DXR) is an innovative medical instrumentation and biotechnology company focused on blood volume measurement. We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology has the potential to improve hospital performance metrics in a broad range of surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved patient outcomes. Our mission is to partner with clinicians to incorporate BVA technology into standard clinical practice and improve the quality of life for patients. For more information, please visit our website at Daxor.com.

Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:

Bret Shapiro

Sr. Managing Partner, CORE IR

516-222-2560

brets@coreir.com

DAXOR ANNOUNCES INITIATION OF FIRST-OF-ITS-KIND MULTICENTER BVA-100® STUDY IN HOSPITALIZED PATIENTS WITH COVID-19

COVID-19 Investigation Commences at NYU Langone Health with Daxor's Blood Volume Analysis Technology

NEW YORK -- July 15, 2020 -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced the initiation of a multicenter prospective study utilizing Daxor's BVA-100 (Blood Volume Analyzer, "BVA") technology in hospitalized COVID-19 patients. NYU Langone Health in New York City is the first site to enroll patients under the leadership of Jan Bakker, MD, PhD.

"Institutions have been using and collecting data on the BVA-guided care of COVID-19 patients since the onset of the pandemic," said Michael Feldschuh, CEO and President of Daxor Corporation. "A multicenter trial is essential to understanding COVID-based volume derangements. We are encouraged by the initial application of the BVA to improve care and outcomes and are confident that the BVA will continue to help physicians detect and manage the significant underlying volume derangements suffered by COVID patients in the ICU."

Jonathan Feldschuh, Chief Scientific Officer of Daxor, stated, "Accurate volume assessment allows for individualized care, ensuring circulatory integrity and optimal tissue perfusion. Our BVA technology provides clinicians with precise volume measurement superior to commonly used indirect estimates. The BVA also offers insights into patients' capillary leak rate, which has been shown to be an early prognostic indicator in critically ill patients. In addition, the use of the blood volume to optimize treatment has been shown to improve outcomes in other clinical settings. We expect to announce additional study sites in the coming weeks."

Daxor's FDA-cleared diagnostic instrument used in critical care can help guide treatment, as the BVA-100 measures patients' blood, plasma and red cell volume and calculates the ideal blood volume that the patient should have, with statistics showing deviations from the patient-specific ideal. The BVA is the only test that provides a unique measure of capillary permeability via its albumin tracer, an important insight into COVID-19 pathophysiology. This study aims to show the implications of COVID as an endothelial disease utilizing this measure.

In a randomized control trial (RCT) published in 2011 in the journal *Shock*, patients at a Level-1 trauma center ICU suffering predominantly from ARDS/sepsis/septic shock/hemorrhagic shock who received BVA-guided care showed significant benefits including a 66% lower mortality rate ($P < 0.03$), reducing mortality from 24% to 8%. Analysis showed 44% of BVA test results led to a

change in treatment strategy (P=0.004) that care teams would not have performed absent the data from the BVA volume status measure.

About Daxor Corporation

Daxor Corporation (NYSE: DXR) is an innovative medical instrumentation and biotechnology company focused on blood volume measurement. We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology has the potential to improve hospital performance metrics in a broad range of surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved patient outcomes. Our mission is to partner with clinicians to incorporate BVA technology into standard clinical practice and improve the quality of life for patients. For more information, please visit our website at Daxor.com.

Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:

Bret Shapiro

Sr. Managing Partner, CORE IR

516-222-2560

brets@coreir.com